Corbus Pharmaceuticals (CRBP) Competitors $4.92 -0.01 (-0.10%) As of 02:02 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock CRBP vs. GOSS, CMPS, SEPN, CADL, DSGN, AVIR, CRVS, MBX, ZYBT, and IMMPShould you be buying Corbus Pharmaceuticals stock or one of its competitors? The main competitors of Corbus Pharmaceuticals include Gossamer Bio (GOSS), COMPASS Pathways (CMPS), Septerna (SEPN), Candel Therapeutics (CADL), Design Therapeutics (DSGN), Atea Pharmaceuticals (AVIR), Corvus Pharmaceuticals (CRVS), MBX Biosciences (MBX), Zhengye Biotechnology (ZYBT), and Immutep (IMMP). These companies are all part of the "pharmaceutical products" industry. Corbus Pharmaceuticals vs. Gossamer Bio COMPASS Pathways Septerna Candel Therapeutics Design Therapeutics Atea Pharmaceuticals Corvus Pharmaceuticals MBX Biosciences Zhengye Biotechnology Immutep Corbus Pharmaceuticals (NASDAQ:CRBP) and Gossamer Bio (NASDAQ:GOSS) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, earnings, media sentiment, valuation, risk, community ranking and dividends. Is CRBP or GOSS more profitable? Corbus Pharmaceuticals' return on equity of -42.28% beat Gossamer Bio's return on equity.Company Net Margins Return on Equity Return on Assets Corbus PharmaceuticalsN/A -42.28% -32.92% Gossamer Bio N/A -127.28%-22.12% Do insiders and institutionals have more ownership in CRBP or GOSS? 64.6% of Corbus Pharmaceuticals shares are held by institutional investors. Comparatively, 81.2% of Gossamer Bio shares are held by institutional investors. 4.0% of Corbus Pharmaceuticals shares are held by insiders. Comparatively, 5.0% of Gossamer Bio shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Which has more risk & volatility, CRBP or GOSS? Corbus Pharmaceuticals has a beta of 3.12, indicating that its stock price is 212% more volatile than the S&P 500. Comparatively, Gossamer Bio has a beta of 1.88, indicating that its stock price is 88% more volatile than the S&P 500. Does the MarketBeat Community believe in CRBP or GOSS? Corbus Pharmaceuticals received 301 more outperform votes than Gossamer Bio when rated by MarketBeat users. Likewise, 67.01% of users gave Corbus Pharmaceuticals an outperform vote while only 66.67% of users gave Gossamer Bio an outperform vote. CompanyUnderperformOutperformCorbus PharmaceuticalsOutperform Votes45567.01% Underperform Votes22432.99% Gossamer BioOutperform Votes15466.67% Underperform Votes7733.33% Do analysts recommend CRBP or GOSS? Corbus Pharmaceuticals currently has a consensus target price of $59.13, suggesting a potential upside of 1,130.49%. Gossamer Bio has a consensus target price of $7.75, suggesting a potential upside of 845.12%. Given Corbus Pharmaceuticals' stronger consensus rating and higher possible upside, equities research analysts plainly believe Corbus Pharmaceuticals is more favorable than Gossamer Bio.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Corbus Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 9 Buy rating(s) 1 Strong Buy rating(s) 3.10Gossamer Bio 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has preferable earnings & valuation, CRBP or GOSS? Corbus Pharmaceuticals has higher earnings, but lower revenue than Gossamer Bio. Gossamer Bio is trading at a lower price-to-earnings ratio than Corbus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCorbus PharmaceuticalsN/AN/A-$44.60M-$3.66-1.31Gossamer Bio$114.70M1.62-$179.82M-$0.26-3.15 Does the media prefer CRBP or GOSS? In the previous week, Corbus Pharmaceuticals had 2 more articles in the media than Gossamer Bio. MarketBeat recorded 3 mentions for Corbus Pharmaceuticals and 1 mentions for Gossamer Bio. Gossamer Bio's average media sentiment score of 0.60 beat Corbus Pharmaceuticals' score of 0.27 indicating that Gossamer Bio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Corbus Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Gossamer Bio 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryCorbus Pharmaceuticals beats Gossamer Bio on 11 of the 17 factors compared between the two stocks. Remove Ads Get Corbus Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CRBP and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CRBP vs. The Competition Export to ExcelMetricCorbus PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$58.65M$6.49B$5.38B$7.21BDividend YieldN/A2.85%4.87%4.05%P/E Ratio-1.026.8622.9517.52Price / SalesN/A189.36356.0485.30Price / CashN/A65.6738.1634.64Price / Book-3.085.666.273.81Net Income-$44.60M$142.11M$3.21B$247.10M7 Day Performance-12.95%-10.96%-7.64%-7.26%1 Month Performance-29.03%-13.94%-2.57%-9.98%1 Year Performance-87.67%-17.92%3.91%-7.33% Corbus Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CRBPCorbus Pharmaceuticals3.2643 of 5 stars$4.92-0.1%$59.13+1,103.0%-87.2%$60.12MN/A-1.0540Gap DownGOSSGossamer Bio3.5224 of 5 stars$1.28-7.9%$9.20+618.8%-15.2%$290.84M$114.70M-4.00180CMPSCOMPASS Pathways3.2306 of 5 stars$3.11+0.3%$21.83+602.0%-70.8%$288.21MN/A-1.41120SEPNSepterna1.939 of 5 stars$6.38+7.8%$34.00+432.7%N/A$283.42M$981,000.000.00N/AGap DownCADLCandel Therapeutics2.1685 of 5 stars$8.66+7.4%$21.00+142.5%+212.5%$281.24M$120,000.00-5.0160Gap DownDSGNDesign Therapeutics1.2197 of 5 stars$4.93+6.0%$8.00+62.3%-4.9%$279.84MN/A-5.8040Gap DownAVIRAtea Pharmaceuticals2.5375 of 5 stars$3.20-0.6%$6.88+115.0%-25.6%$273.68MN/A-1.5570Gap DownCRVSCorvus Pharmaceuticals2.1927 of 5 stars$4.25-1.4%$12.38+191.2%+70.9%$273.09MN/A-4.5730MBXMBX Biosciences2.1333 of 5 stars$8.13+3.0%$37.25+358.2%N/A$271.74MN/A0.0036Positive NewsZYBTZhengye BiotechnologyN/A$5.70+16.8%N/AN/A$268.85M$189.75M0.00278News CoverageGap DownHigh Trading VolumeIMMPImmutep1.4664 of 5 stars$1.84-2.1%$8.50+362.0%-36.1%$267.83M$5.14M0.002,021 Remove Ads Related Companies and Tools Related Companies GOSS Alternatives CMPS Alternatives SEPN Alternatives CADL Alternatives DSGN Alternatives AVIR Alternatives CRVS Alternatives MBX Alternatives ZYBT Alternatives IMMP Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CRBP) was last updated on 4/4/2025 by MarketBeat.com Staff From Our PartnersTrump Allies Confirm Exec Order 14024 Triggers Dollar CollapseExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredYour Retirement Is Caught in the CrossfireWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredCaught on Camera: Elon Musk’s “Area 51”You won’t believe what tech legend Jeff Brown found in what he calls Elon Musk’s “Area 51.” (Click here to see...Brownstone Research | SponsoredRUTHLESS Musk Move >> coming June 1?Elon Musk has made headlines with everything from mass layoffs to political drama — but his next move could sh...Paradigm Press | SponsoredNearly $3 Trillion Gone…Nearly $3 trillion disappeared from the stock market on Thursday morning. According to Whitney Tilson - a f...Stansberry Research | SponsoredHow you could profit from Elon’s latest AI breakthroughEvery single one of Elon's projects minted an entire new class of millionaires. And xAI could be next in li...Behind the Markets | Sponsored🥾⛏️👷♂️ What I Learned From Numerous Mine Visits...Twenty years ago, I made a decision that changed my life. Instead of sitting behind a desk analyzing mining...Golden Portfolio | SponsoredTrump’s betrayal exposed Fair warning: this will not make for easy viewing. Especially if you voted for Trump, put your faith in hi...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Corbus Pharmaceuticals Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Corbus Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
